Numerical impairment of nestin(+) bone marrow niches in acute GvHD after allogeneic hematopoietic stem cell transplantation for AML.
M MedingerW KrengerA JakabJ HalterAndreas S BuserC BucherJ PasswegAlexandar TzankovPublished in: Bone marrow transplantation (2015)
The nestin(+) perivascular bone marrow (BM) stem cell niche (N(+)SCN) may be involved in GvHD. To investigate whether acute GvHD (aGvHD) reduces the number of N(+)SCN, we examined patients with AML who had undergone allogeneic hematopoietic stem cell transplantation. In the test cohort (n=8), the number of N(+)SCN per mm(2) in BM biopsies was significantly reduced in aGvHD patients at the time of aGvHD compared with patients who did not have aGvHD (1.2±0.78 versus 2.6±0.93, P=0.04). In the validation cohort (n=40), the number of N(+)SCN was reduced (1.9±0.99 versus 2.6±0.90 N(+)SCN/mm(2), P=0.05) in aGvHD patients. Receiver operating curves suggested that the cutoff score that best discriminated between patients with and without aGvHD was 2.29 N(+)SCN/mm(2). Applying this cutoff score, 9/11 patients with clinically relevant aGvHD (⩾grade 2) and 13/20 with any type of GvHD had decreased N(+)SCN numbers compared with only 10/29 patients without clinically relevant aGvHD (P=0.007) and 6/20 patients without any type of GvHD (P=0.028). In patients tracked over time, N(+)SCN density returned to normal after aGvHD resolved or remained stable in patients who did not have aGvHD. Our results show a decrease in the number of N(+)SCN in aGvHD.
Keyphrases
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- bone marrow
- acute myeloid leukemia
- newly diagnosed
- ejection fraction
- acute lymphoblastic leukemia
- stem cells
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- intensive care unit
- mesenchymal stem cells
- hepatitis b virus
- patient reported outcomes
- cell therapy
- extracorporeal membrane oxygenation